


Clinical Procedure Evaluation.



The Science 37 Metasite for Dermatology

Dr. Robert Stavert Medical Director, Dermatology



- Board-certified dermatologist
- Expertise in implementation of telemedicine services
- Multiple publications in leading peer-reviewed journals
- Experience as PI, and conducting clinical assessments through telemedicine

- **United States**
- **Canada**
- **Europe**

INDICATIONS

- Atopic Dermatitis
- Acne Vulgaris
- Psoriasis
- Pemphigus Vulgaris
- Rosacea
- Herpes Labialis
- Netherton Syndrome
- Lupus erythematosus

SCIENCE 37 DERMATOLOGY EXPERIENCE

- 20 trials conducted
- 222 total providers accessible for trials
- Phases I, II, III, and IV

SOURCE OF SUBJECT ACCESS

- Provider Network
 - 34,000 physicians reaching 33M patients
- Partnerships
 - Patient groups
 - Registries
 - Labs and Pharmacies
 - Associations
- Science 37 patient community of 530,000+
- Digital media
- Third party vendors

QUOTE FROM CASE STUDY

"We are seeing key advancements in hybrid/ dermatology trials, in one trial all images and metadata are being used for AI development."

CASE STUDY LINK

[Dermatology Case Study](#)

The Science 37 Metasite for CNS - Psychiatry

Dr. Christopher Reist Medical Director, Psychiatry and Behavioral Sciences



- Conducting clinical trials since 1990
- Recipient of NIH and DoD funding for clinical trials
- 80+ peer reviewed publications
- Recognized thought leader
- Experience with:
 - Multicenter trial oversight
 - Trial design
 - Outcomes research

- **United States**
- **Canada**

INDICATIONS

- Major Depressive Disorder
- Postpartum Depression
- Post-Traumatic Stress Disorder (pharmacological and psychotherapy tx)
- Schizophrenia
- Bipolar Disorder
- Impulse control disorders
- Alzheimer's Disease and MCI

SCIENCE 37 PSYCHIATRY EXPERIENCE

- 5+ Trials Conducted
- 407 total providers accessible for trials (CNS)
- Phase II, III, IV trials

SOURCE OF SUBJECT ACCESS

- Provider Network
 - 34,000 physicians reaching 33M patients
- Partnerships
 - Patient groups
 - Registries
 - Labs and Pharmacies
 - Associations
- Science 37 Patient Community of 530,000+
- Digital media
- Third party vendors

QUOTE FROM INVESTIGATOR

"This model proved that DCTs are safe and efficient—supporting MDD patients in a virtual setting, enabling real-time responses to adverse events. The FDA accepted a telemedicine-based MADRS as an endpoint."

CASE STUDY LINK

[CNS Case Study](#)

The Science 37 Metasite for CNS – Neurology

Dr. David Kudrow Medical Director, Neurology



- Board certified neurologist, practices general neurology with an emphasis on headache disorders.
 - Principal investigator in more than 120 phase II, III and IV clinical trials in migraine, Alzheimer's disease, epilepsy, neuropathic pain and other neurological indications.
 - Numerous publications in peer reviewed journals.
-
- **United States**
 - **Canada**
 - **Europe**

INDICATIONS

- MS Biomarker
- Pediatric RLS
- Late-Onset Tay Sach's
- Phase I/II Homocysteinuria (Will be starting Phase III Homocysteinuria)
- Phase III Phenylketonuria
- Parkinson's Disease
- Restless Leg Syndrome
- Huntington's Disease
- Seizure
- Migraine

SCIENCE 37 NEUROLOGY EXPERIENCE

- 12+ Trials Conducted
- 407 total providers accessible for trials (CNS)
- Phase I, II, III, IV

SOURCE OF SUBJECT ACCESS

- Provider Network
 - 34,000 physicians reaching 33M patients
- Partnerships
 - Patient groups
 - Registries
 - Labs and Pharmacies
 - Associations
- Science 37 Patient Community of 530,000+
- Digital media
- Third party vendors

QUOTE FROM SPONSOR

"Working with the Metasite model allows sponsors to supersize their impact!"

CASE STUDY LINK

[CNS Case Study](#)

The Science 37 Metasite for CNS – Neurology

Dr. David Kudrow Medical Director, Neurology



- Board certified neurologist, practices general neurology with an emphasis on headache disorders.
 - Principal investigator in more than 120 phase II, III and IV clinical trials in migraine, Alzheimer's disease, epilepsy, neuropathic pain and other neurological indications.
 - Numerous publications in peer reviewed journals.
-
- **United States**
 - **Canada**
 - **Europe**

INDICATIONS

- MS Biomarker
- Pediatric RLS
- Late-Onset Tay Sach's
- Phase I/II Homocysteinuria (Will be starting Phase III Homocysteinuria)
- Phase III Phenylketonuria
- Parkinson's Disease
- Restless Leg Syndrome
- Huntington's Disease
- Seizure
- Migraine

SCIENCE 37 NEUROLOGY EXPERIENCE

- 12+ Trials Conducted
- 407 total providers accessible for trials (CNS)
- Phase I, II, III, IV

SOURCE OF SUBJECT ACCESS

- Provider Network
 - 34,000 physicians reaching 33M patients
- Partnerships
 - Patient groups
 - Registries
 - Labs and Pharmacies
 - Associations
- Science 37 Patient Community of 530,000+
- Digital media
- Third party vendors

QUOTE FROM SPONSOR

"Working with the Metasite model allows sponsors to supersize their impact!"

The Science 37 Metasite for Respiratory

Dr. Debra Weinstein Vice President, Internal Medicine



- Has served as an investigator on more than 250 clinical trials
- Diplomate of the American Board of Internal Medicine
- Recognized by Town and Country Magazine as a Top Internist

- **United States**
- **Canada**
- **Europe**

INDICATIONS

- Refractory Chronic Cough
- CRSwNP + Asthma
- Pulmonary / Respiratory Complications in Patients with NMD
- COPD

SCIENCE 37 RESPIRATORY EXPERIENCE

- 9 trials completed
- 234 total providers accessible for trials
- Phase I, III, and IV trials

SOURCE OF SUBJECT ACCESS

- Provider Network
 - 34,000 physicians reaching 33M patients
- Partnerships
 - Patient groups
 - Registries
 - Labs and Pharmacies
 - Associations
- Science 37 Patient Community of 530,000+
- Digital media
- Third party vendors

QUOTE FROM INVESTIGATOR

"Our respiratory-experienced mobile nurses work under the supervision of our investigators and bring the newest health tech into the home. We excel in collecting high quality spirometry data during our home visits"

CASE STUDY LINK

[Respiratory Case Study](#)

The Science 37 Metasite for Infectious Disease

Dr. Debra Weinstein Vice President, Internal Medicine



- Has served as an investigator on more than 250 clinical trials
- Diplomat of the American Board of Internal Medicine
- Recognized by Town and Country Magazine as a Top Internists

- **United States**
- **Canada**
- **Europe**

INDICATIONS

- COVID-19 Treatment
- COVID-19 Prevention
- RSV prevention
- Clostridium Difficile
- Vaccine Development

SCIENCE 37 INF. DISEASE EXPERIENCE

- 30 trials completed
- 127 total providers accessible for Infectious Disease trials
- Phase I, II, III, IV trials

SOURCE OF SUBJECT ACCESS

- Provider Network
 - 34,000 physicians reaching 33M patients
- Partnerships
 - Patient groups
 - Registries
 - Labs and Pharmacies
 - Associations
- Science 37 Patient Community of 530,000+
- Digital media
- Third party vendors

QUOTE FROM INVESTIGATOR

"The pandemic certainly brought out the urgent need for flexibility and access to participants with infectious disease. It allowed us to expand our therapeutic reach into many aspects of infectious disease treatment and prevention."

CASE STUDY LINK

[Infectious Disease Case Study](#)

The Science 37 Metasite for Oncology

Dr. Shaalan Beg Vice President, Oncology



- Conducting clinical trials since 2011
- Served on steering committee of multiple multicenter trials
- Invited speaker for international oncology conferences

- **United States**
- **Canada**
- **Europe**

INDICATIONS

- Precision oncology trials
- Population health and early detection studies
- Long term follow up for Cell/Gene therapy
- Expanded access protocols

SCIENCE 37 ONCOLOGY EXPERIENCE

- 36 trials conducted
- 617 total providers accessible for Oncology trials
- Phase II, III, and IV

SOURCE OF SUBJECT ACCESS

- Provider Network
 - 34,000 physicians reaching 33M patients
- Partnerships
 - Patient groups
 - Registries
 - Labs and Pharmacies
 - Associations
- Science 37 Patient Community of 530,000+
- Digital media
- Third party vendors

QUOTE FROM SPONSOR

"This trial was extremely impactful, as treatments were needed at home every 3 weeks. With patients receiving up to 18 cycles over 12.5 months, bringing the treatment to the patient significantly reduced burden, improving retention. As stated by the Medical Director "All clinical trials are special but this one is above and beyond anything in my oncology career."

CASE STUDY LINK

[Oncology Case Study](#)

The Science 37 Metasite for Cardiology

Dr. Jonathan Cotliar Chief Medical Officer



- An investigator on a number of virtual clinical trials, in addition to supporting regulatory strategy.
- Board-certified in both internal medicine and dermatology.
- More than 25 clinical trials

- **United States**
- **Canada**
- **Europe**

INDICATIONS

- Atherosclerosis
- Hyperlipidemia
- Hypertension
- Coronary artery disease (CAD)
- Familial hypercholesterolemia
- Atrial fibrillation
- Rare (i.e. Ehlers-Danlos Syndrome)

SCIENCE 37 CARDIOLOGY EXPERIENCE

- 5 trials conducted
- 698 total providers accessible for trials
- Phase II, and III

SOURCE OF SUBJECT ACCESS

- Provider Network
 - 34,000 physicians reaching 33M patients
- Partnerships
 - Patient groups
 - Registries
 - Labs and Pharmacies
 - Associations
- Science 37 Patient Community of 530,000+
- Digital media
- Third party vendors

QUOTE FROM CASE STUDY

"This trial was advanced in that we leveraged at-home bedside cardiac assessments performed by the trained Science 37 nurse."

CASE STUDY LINK

[Cardiology Case Study](#)

The Science 37 Metasite for Rare Disease

Dr. Jonathan Cotliar Chief Medical Officer



- An investigator on a number of virtual clinical trials, in addition to supporting regulatory strategy.
- Board-certified in both internal medicine and dermatology.
- More than 25 clinical trials

- **United States**
- **Canada**
- **Europe**

INDICATIONS

- Late Onset Tay-Sachs and Sandhoff disease (III)
- Cholestatic pruritus due to primary biliary cholangitis (III)
- Vascular Ehler-Danlos Syndrome (III)
- Congenital Adrenal Hyperplasia (pre-screening for gene therapy)
- Homocystinuria (natural history, I/II, III)
- Pemphigus Vulgaris (IIIb)
- Congenital Sucrase-Isomaltase Deficiency (VI)
- Phenylketonuria (III)

SCIENCE 37 RARE DISEASE EXPERIENCE

- 9 Rare Disease Studies
- 34,000 providers accessible
- Natural history, Phase I/II, III, IV, pre-screening

SOURCE OF SUBJECT ACCESS

- Provider Network
 - 34,000 physicians reaching 33M patients
- Partnerships
 - Patient groups
 - Registries
 - Labs and Pharmacies
 - Associations
- Science 37 Patient Community of 530,000+
- Digital media
- Third party vendors

QUOTE FROM SPONSOR

"88% of those living with rare disease would consider an investigational treatment, yet only 16% are participating in trials. We have to close that gap"

CASE STUDY LINK

[Rare Disease Case Study](#)